SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: Poor Man -, buythebuy
Search This Board:
Last Post: 9/25/2016 11:09:01 PM - Followers: 185 - Board type: Free - Posts Today: 22


Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
BHRT - Daily Candlesticks


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
USRM News: Statement of Changes in Beneficial Ownership (4) 09/23/2016 04:08:00 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 09/23/2016 04:05:49 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 09/23/2016 04:04:54 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 09/23/2016 04:03:09 PM
USRM News: Statement of Changes in Beneficial Ownership (4) 09/23/2016 04:01:52 PM
#17615  Sticky Note USRM DISMISSED IN ONE SUIT! buythebuy 09/24/16 08:21:11 PM
#17554  Sticky Note MAJOR NEW LAWSUIT against U.S. Stem Hornet Driver 09/19/16 05:59:27 PM
#17638   Agreed. Time for USRM to move Go $USRM $Pistol Pete$ 09/25/16 11:09:01 PM
#17637   Yes, it was and USRM is not liable buythebuy 09/25/16 11:08:28 PM
#17636   $USRM case dismissed [IMG] $Pistol Pete$ 09/25/16 11:06:34 PM
#17635   Quote "Bleak" lol. Look at all the litigation. USRM buythebuy 09/25/16 10:44:53 PM
#17634   Gonna be a tough sell in front of Poor Man - 09/25/16 10:42:17 PM
#17633   Agreed, total waste of Miguel's time...and the risk Poor Man - 09/25/16 10:23:32 PM
#17632   Great...good to hear. Hornet Driver 09/25/16 10:17:44 PM
#17631   Bleak is the only way to describe a Poor Man - 09/25/16 10:12:57 PM
#17630   Yeah, I read it. Thanks, good and Poor Man - 09/25/16 10:05:07 PM
#17629   Yeah, that is common on many of these Garyst 09/25/16 08:21:16 PM
#17628   LAWSUIT ALLEGES...USRM "BARELY SURVIVING" Hornet Driver 09/25/16 08:03:37 PM
#17627   Last post, I think it was blank by Hornet Driver 09/25/16 05:49:16 PM
#17626   Poor Man - 09/25/16 05:36:44 PM
#17625   Agree, BK if indeed a "COURT APPOINTED RECEIVER" Hornet Driver 09/25/16 05:31:49 PM
#17624   GOT IT! Poor Man - 09/25/16 05:30:44 PM
#17623   Poor Man- Hornet Driver 09/25/16 05:27:40 PM
#17622   Hey, HD - I'll stay online for another Poor Man - 09/25/16 05:24:26 PM
#17621   Poor Man- Hornet Driver 09/25/16 04:58:57 PM
#17620   Quote, "The settlement of the U.S. Stem Cell Hornet Driver 09/25/16 04:56:12 PM
#17619   Things are not as bleak as some people buythebuy 09/25/16 04:05:29 PM
#17618   Use of misdirection. Poor Man - 09/25/16 03:26:34 PM
#17617   Excellent news! Clearly states it their in your screenshot! Garyst 09/25/16 02:40:24 PM
#17616   LOL, "USRM DISMISSED IN ONE SUIT! " Hornet Driver 09/24/16 09:28:28 PM
#17615   USRM DISMISSED IN ONE SUIT! buythebuy 09/24/16 08:21:11 PM
#17614   Poor Man- Hornet Driver 09/23/16 07:22:51 PM
#17613   WOW!!!!...This will only convince a judge that a Poor Man - 09/23/16 06:04:16 PM
#17612   Hornet Drive, Poor Man - 09/23/16 05:47:06 PM
#17611   FORM 4's filed, LOL !! Tomas "OWNERSHIP RIGHTS?" Hornet Driver 09/23/16 05:29:37 PM
#17610   Poor Man- Hornet Driver 09/23/16 05:23:58 PM
#17609   Another Way to View Excessive Officer's Compensation Poor Man - 09/23/16 05:15:57 PM
#17608   Correct, typically those 10k's are well above 10k Garyst 09/23/16 03:47:31 PM
#17607   Quote NO LOL, "Under 1 million shares thru Hornet Driver 09/23/16 03:43:25 PM
#17606   Close to 100% buys today. Garyst 09/23/16 02:50:21 PM
#17605   I saw one ask slap for 100k shares buythebuy 09/23/16 02:41:44 PM
#17604   So far holding in the Green all day. Garyst 09/23/16 02:40:35 PM
#17603   I will be curious to see what power buythebuy 09/23/16 02:33:02 PM
#17602   Under 1 million shares thru 02 now Garyst 09/23/16 02:05:18 PM
#17601   Lawsuit..TWO SALARIES..CONSUME ALL REVENUES ! Hornet Driver 09/23/16 01:47:50 PM
#17600   Green on a Friday is a positive sign buythebuy 09/23/16 12:59:31 PM
#17599   Saw that. Good to see some Green today. Garyst 09/23/16 12:42:16 PM
#17598   Interesting 10 share paint down early in the buythebuy 09/23/16 12:11:10 PM
#17597   Great DD h2o. Nice to see USRM green buythebuy 09/23/16 12:08:35 PM
#17596   Poor Man- Hornet Driver 09/23/16 11:06:47 AM
#17595   The lawsuit is bad news for Miguel. If Poor Man - 09/23/16 07:44:52 AM
#17594   It is general knowledge that stem cells work mind1 09/23/16 07:23:35 AM
#17592   Federal Right to Try; hopefully not déjà vu H20-Life 09/23/16 06:07:33 AM
#17591   Patients’ rights H20-Life 09/23/16 06:06:36 AM
#17590   Richard Jaffe, ESQ. H20-Life 09/23/16 06:05:43 AM
#17589   FDA Draft Stem Cell Guidance Documents Exposed as H20-Life 09/23/16 04:27:04 AM